Are ResMed shares still undervalued in 2024?

Is this beaten down sleep treatment giant still cheap?

| More on:
Young woman thinking with laptop open.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ResMed Inc (ASX: RMD) shares had a very tough time in 2023.

Concerns over the emergence of weight loss wonder drugs led to many investors selling down the sleep treatment company's shares.

This ultimately led to the ResMed share price losing 18% of its value over the 12 months.

Though, it is worth noting that things were looking a lot worse for shareholders until a decent rebound in the latter part of the year.

For example, from 1 January through to 31 October, ResMed shares were down 30%.

The question now, though, is whether its shares are still undervalued or not. Let's find out.

Are ResMed shares still undervalued?

While the company's shares are now trading almost 25% above 2023's low, a number of brokers still see material upside for them this year.

Goldman Sachs, for example, currently has a buy rating and a $32 price target on its shares. This implies a potential upside of 21% for investors over the next 12 months.

Elsewhere, Morgans has an add rating and a $32.74 price target, which suggests a potential upside of 24%.

And finally, the bulls at Macquarie have an even higher price target on the company's shares. They currently have an outperform rating and a $33.40 price target, which implies a potential upside of approximately 27% for investors over the next 12 months.

All in all, based on what these brokers are saying, it is fair to say that they believe ResMed shares remain undervalued in 2024.

All eyes will be on the company this month when it releases its second quarter and half-year update. That is due to be released on 25 January and should give investors an indication of how Ozempic's growing popularity is or is not impacting its performance.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group, Macquarie Group, and ResMed. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »